Use of Somatropin in Turner Syndrome

Novo Nordisk A/S57 enrolled

Overview

This trial is conducted in Europe. The aim of this trial is to study the dose-response relationship and effect of somatropin (Norditropin®) on final height in girls with Turner Syndrome.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Genetic Disorder Turner Syndrome

Interventions

somatropinDRUG

2.9 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached

somatropinDRUG

4.3 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached

Eligibility

Sex: FEMALEMin age: 2 YearsMax age: 11 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Turner Syndrome * Not previously treated with growth hormone or androgen * Well-documented height over the previous 12 months * Informed consent of parents (and child if appropriate) Exclusion Criteria: * Growth hormone (GH) deficiency based on a GH stimulation test

Locations (1)

Novo Nordisk Investigational Site

Crawley, United Kingdom

Outcomes

Primary Outcomes

Final height in cm

Secondary Outcomes

Ratio between change in bone age and change in chronological age

Age at onset of puberty

Adverse events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.